Blueprint Medicines Corp

Blueprint Medicines — Technical Presentation (December 2016)

39 slides from Blueprint Medicines's technical presentation, Dec 1, 2016

  1. Slide 1: 28th EORTC-NCI-AACR Symposium Summary of BLU-285 and BLU-554 Presentations

    28th EORTC-NCI-AACR Symposium Summary of BLU-285 GIST Oral Presentation & Summary of BLU-554 HCC Poster Presentation Blueprint Medicines Corporation Investor Webcast & Conference Call December 1, 2016

  2. Slide 2: Conference Call Participants

    Conference Call Participants Jeff Albers Chief Executive Officer, Blueprint Medicines Andy Boral, M.D. Chief Medical Officer, Blueprint Medicines Michael Heinrich, M.D. Oregon Health & Sciences University

  3. Slide 3: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,”

  4. Slide 4: Proprietary Compound Library and Target Discovery Engine

    Proprietary Compound Library Text Here Text Here Unique collection of small molecule kinase inhibitors Provides high-quality medicinal chemistry starting points Ability to craft drug candidates to previously difficult targets New insights into the biology of kinases as disease drivers Identification

  5. Slide 5: Robust Portfolio with Diverse Clinical Stage Assets

    Robust Portfolio with Diverse Clinical Stage Assets Initial Diseases Discovery Pre-Clinical Clinical Development Commercial Rights GIST PDGFRα D842V and KIT Exon 17 Mutations HCC FGFR4 Inhibitor SM KIT D816V Mutations NSCLC, Thyroid RET Fusions & Resistant Mutants FLC (Fibrolamellar Carcinoma) PRKAC

  6. Slide 6: Preliminary safety and activity of BLU-285 in advanced GIST

    Preliminary safety and activity in a first-in-human Phase 1 study of BLU-285, a potent, highly selective inhibitor of KIT and PDGFR activation loop mutants in advanced gastrointestinal stromal tumor (GIST) Michael Heinrich1, Robin Jones2, Patrick Schoffski3, Sebastian Bauer4, Margaret von Mehren5,

  7. Slide 7: Disclosures

    BLU-285 is an investigational agent currently in development by Blueprint Medicines Corporation (Blueprint Medicines) Dr. Michael Heinrich is an investigator for Blueprint Medicines’ ongoing Phase 1 study in unresectable gastrointestinal stromal tumor Dr. Michael Heinrich has the following disclosur

  8. Slide 8: Gastrointestinal Stromal Tumor (GIST)

    Cancer of the interstitial cells of Cajal Primary tumor usually presents as a stomach or intestinal mass Metastatic recurrences spread to liver, peritoneum, and other distant sites Chemotherapy has no impact Gastrointestinal Stromal Tumor (GIST) Most common GI sarcoma Primary mutational hotspots KIT

  9. Slide 9: Advanced GIST has high medical need

    Advanced GIST has high medical need Activation loop mutations are associated with resistance to therapy Approved agents are ineffective against PDGFR D842V ORR ~ 0% mPFS ~ 3 months Primary resistance Secondary resistance Prevalence Resistance mutation Primary Secondary KIT Exon 17 ~ 1% 2L ~ 20% 3L ~

  10. Slide 10: BLU-285 is a highly potent and selective inhibitor of KIT and PDGFR mutants

    BLU-285 imatinib sunitinib regorafenib BLU-285 is a highly potent and selective inhibitor of KIT and PDGFR activation loop mutants Tumor regression in KIT exon 11/17* mutant GIST PDX Biochemical profiles Compound PDGFR D842V IC50 nM KIT D816V IC50 nM KIT V560G/D816V IC50 nM BLU-285 0.24 0.27 0.10

  11. Slide 11: BLU-285 Phase 1 study design

    BLU-285 Phase 1 study Advanced GIST MTD Dose expansion Unresectable GIST after imatinib and ≥ 1 other TKI PDGFR D842-mutant GIST BLU-285 continuous once daily oral dosing Dose escalation Primary objectives – determine the MTD and RP2D, and assess safety and tolerability Secondary objectives – PK, mu

  12. Slide 12: Demography and baseline patient characteristics

    Parameter All patients, N = 36 Age (years), median (range) 61 (41 – 77) n (%) GIST subtype KIT mutant PDGFR mutant 18 (50) 18 (50) Metastatic Disease 35 (97) Largest target lesion size (cm) ≤ 5 > 5 – ≤ 10 > 10 pending 8 (22) 12 (33) 14 (39) 2 (6) #Prior TKI, median (range) ≤ 2 > 2 3.5 (0 – 12) 12 (3

  13. Slide 13: Initial dose escalation results

    Patients with unresectable GIST Prior imatinib and ≥ 1 TKI PDGFR D842 mutation regardless of prior therapy 3 + 3 dose escalation with additional accrual to dose levels declared safe at a dose escalation meeting 36 patients enrolled over 12 months MTD has not been reached Initial dose escalation resu

  14. Slide 14: BLU-285 pharmacokinetics support once daily dosing

    10000 1000 100 10 1 0 30 mg 60 mg 90 mg 135 mg 200 mg 300 mg Time (hour) 0 10 20 30 10000 1000 100 10 1 0 Plasma concentration (ng/mL) Time (hour) Half-life > 24 hour, supporting QD dosing Relatively rapid absorption: Tmax ~ 2 – 8 hr Accumulation in plasma: 2.5 – 4.7 -fold after 15 days Exposure at

  15. Slide 15: Radiographic response in PDGFR D842V GIST

    65 yo female, Primary Gastric GIST, PDGFR D842V Previous surgical de-bulking: stomach; peritoneal metastases x 2; colon Prior response to crenolanib followed by progression Progression on prior dasatinib (no response) Ongoing at Cycle 13 with confirmed partial response (-52% per RECIST 1.1) Radiogr

  16. Slide 16: Strong clinical activity against PDGFR D842-mutant GIST

    Strong clinical activity against PDGFR D842-mutant GIST at all dose levels Maximum reduction – sum of diameter change from Baseline (%) 30 PDGFRα Exon 14 PDGFRα D842 20 10 0 –10 –20 –30 –40 –50 –60 200 60 60 60 60 135 200 90 90 135 200 135 90 135 30 PR SD PD 14 out of 14 D842-mutant patients with tu

  17. Slide 17: Radiographic response in heavily pretreated KIT Exon 11/17 GIST

    57 year old male, KIT Exon 11 (delWK557-8)/Exon 17 (D816V) mutations Prior imatinib, sunitinib, nilotinib, sorafenib, imatinib + BKM120 Ongoing at Cycle 8 with confirmed partial response per RECIST 1.1 Radiographic response per RECIST 1.1 in heavily pretreated KIT Exon 11/17 GIST (dose level 4, 135

  18. Slide 18: KIT GIST - early dose-response relationship

    KIT GIST - early dose-response relationship Maximum reduction – sum of diameter change from baseline (%) 80 70 60 50 40 30 20 10 0 -10 -20 -30 -40 -50 -60 -70 Off treatment # BLU-285 30 – 90 mg BLU-285 135 – 300 mg 90 60 30 30 90 30 60 300 135 200 300 300 135 PD SD PR # # # # # # Patient # NB: The v

  19. Slide 19: Best radiographic response with BLU-285 per RECIST 1.1

    Best radiographic response with BLU-285 per RECIST 1.1 Of 7 partial responses, 6 confirmed; 1 pending (still on treatment) DCR, disease control rate Best response (per investigator) PDGFR N=15 n (%) KIT N=13 n (%) Total N=28 n (%) PR 6 (40) 1 (8) 7 (25) SD 9 (60) 6 (46) 15 (54) DCR (PR +SD) 15 (100

  20. Slide 20: BLU-285: GIST treatment duration

    BLU-285: GIST treatment duration Each cycle is 28 days in duration C1 C2 C3 C4 C5 C6 C7 C8 C9 C10 C11 C12 C13 C14 C15 Treatment Duration P a t i e n t 2.8 months 6 months Ongoing PD SD PR PDGFR KIT

  21. Slide 21: Adverse events associated with BLU-285

    No DLTs or treatment-related Grade 4 – 5 AEs No patient discontinued BLU-285 due to treatment-related toxicity 11 (31%) patients had Grade 3 or higher AEs; of these, 3 were considered treatment-related: 1 patient with Grade 3 nausea and vomiting 1 patient with Grade 3 anemia and intratumoral hemorrh

  22. Slide 22: Summary

    BLU-285 has been well tolerated on a QD schedule at doses of 30 – 400 mg Half-life > 24 hours, supports QD dosing BLU-285 demonstrates strong clinical activity in PDGFR D842-mutant GIST at all dose levels Significant anti-tumor activity in TKI-resistant, KIT-mutant GIST observed at doses ≥ 135 mg wi

  23. Slide 23: Acknowledgments

    We thank the participating patients, their families, all study co-investigators, and research coordinators at the following institutions: Oregon Health & Science University Royal Marsden Hospital/Institute for Cancer Research Leuven Cancer Institute University of Essen Fox Chase Cancer Center Erasmu

  24. Slide 24: First-in-human study of BLU-554 in HCC

    First-in-human study of BLU-554, a potent, highly selective FGFR4 inhibitor designed for hepatocellular carcinoma (HCC) with FGFR4 pathway activation Richard Kim1, Sunil Sharma2, Tim Meyer3, Debashis Sarker4, Teresa Macarulla5, Max Sung6, Su Pin Choo7, Hongliang Shi8, Oleg Schmidt-Kittler8, Corinne

  25. Slide 25: FGFR4 signaling pathway is a promising new driver for HCC

    The FGFR4 signaling pathway is a promising new driver for a molecularly targeted therapy for HCC Clinical Opportunity Liver cancer, most often HCC, is 2nd leading cause of cancer death worldwide Sorafenib only approved drug, no approved 2nd line therapy Response rate ~2%; median time to progression

  26. Slide 26: FGFR4 activation may result from FGF19 expression

    FGFR4 activation may result from FGF19 being expressed by either endocrine or autocrine physiology HBV, hepatitis B virus; HCV, hepatitis C virus; NASH, nonalcoholic steatohepatitis; KLB, Klotho‑β

  27. Slide 27: BLU-554 is a potent and highly selective inhibitor of FGFR4

    BLU-554 is a potent and highly selective inhibitor of FGFR4 Study days Hep3B xenograft model FGF19 overexpression with amplification 2,000 1,500 1,000 500 0 5 Tumor volume (mm3) 0 10 15 20 25 Vehicle BLU-554 10 mg/kg BLU-554 30 mg/kg BLU-554 100 mg/kg LIX-066 xenograft model FGF19 overexpression wit

  28. Slide 28: BLU-554 Phase 1 study design

    BLU-554 Phase 1 study Part 1: Dose Escalation Part 2: Dose Expansion Enrollment Ongoing Completed Endocrine IHC <1%, FISH-, N=15 Autocrine IHC >1%, FISH- , N=15 Autocrine IHC >1%, FISH+, N=15 3+3 Dose Escalation Key inclusion criteria: Unresectable HCC Child-Pugh class A with no clinically apparent

  29. Slide 29: Demography and baseline patient characteristics

    Parameter All patients, N = 25 Age (years), median (range) 61 (19 – 81) n (%) Gender – Male 19 (76) Etiology Non-viral HBV HCV Other/unknown 4 (16) 8 (32) 4 (16) 9 (36) Metastatic Disease 17 (68) FGF19 IHC IHC ≥ 1% (IHC+) IHC < 1% (IHC-) Unknown 10 (40) 10 (40) 5 (20) FGF19 FISH FISH+ FISH- Unknown

  30. Slide 30: Initial dose escalation results

    Initial dose escalation results BLU-554 mg/day Patients treated by dose N = 25 DLT 140 3 0 280 3 0 420 3 + 3 enrichment 0 600 3 + 3 enrichment 0 900 7 2 Patients with unresectable HCC ± prior sorafenib 3 + 3 dose escalation with additional accrual to previous dose levels 25 patients enrolled over 12

  31. Slide 31: Five of FGF19 IHC+ patients with radiographic tumor shrinkage

    Five of 10 FGF19 IHC+ patients with radiographic tumor shrinkage PD, progressive disease; PR, partial response; SD, stable disease * Case study 1; ** Case study 2 25 patients in the first 5 dose escalation cohorts were evaluable for clinical activity (doses ranging from 140 mg -900 mg QD) 12 patient

  32. Slide 32: Case study 1: Radiographic response in alcohol-related HCC

    RECIST, Response Evaluation Criteria in Solid Tumors Case study 1: Radiographic response per RECIST in patient with alcohol-related cirrhosis and advanced HCC (dose level 2, 280 mg) Week 16, confirmed partial response (-44% per RECIST) Baseline 81 year old male; alcohol-related cirrhosis and metasta

  33. Slide 33: Case study 2: Radiographic response in HBV-related HCC

    Case study 2: Radiographic response per RECIST in patient with HBV-related advanced HCC (dose level 4, 600 mg) Week 16, stable disease (-15% per RECIST) Baseline 64 year old male; HBV-related HCC; BCLC stage C with macrovascular invasion; prior sorafenib; ongoing at cycle 6 Ki-67 ~40% Ki-67 ~ 5% Pre

  34. Slide 34: Blood pharmacodynamic markers demonstrated FGFR4 pathway inhibition

    Blood pharmacodynamic markers demonstrated FGFR4 pathway inhibition at all doses Pre Post Pre Post Pre Post Pre Post Pre Post Cholesterol 140 mg 280 mg 420 mg 600 mg 900 mg 80 120 180 280 mg/dl Pre Post Pre Post Pre Post Pre Post Pre Post 10 100 1000 10000 FGF19 140 mg 280 mg 420 mg 600 mg 900 mg pg

  35. Slide 35: BLU-554 pharmacokinetics

    BLU-554 pharmacokinetics Half-life of ~10 hours Rapid absorption: Tmax ~1–3 hours Exposure increases over the 140–900 mg dose range with significant AUC overlap between 600 and 900 mg dose levels BLU-554 plasma concentration: cycle 1, day 1 0 5 10 15 20 25 100 1000 10000 100000 Time (h) 140 mg 280 m

  36. Slide 36: Adverse events associated with BLU-554

    Adverse events associated with BLU-554 2 (8%) patients experienced DLTs at 900 mg: Grade 3 abdominal pain (1 patient); Grade 3 fatigue (1 patient) 2 (8%) patients discontinued BLU-554 due to treatment-related toxicity: Grade 3 hemorrhage (1 patient); Grade 4 AST increase (1 patient) 17 (68%) patient

  37. Slide 37: Summary

    Summary Proof-of-concept established for highly selective targeting of FGFR4 with BLU-554 in advanced HCC 5 of 10 FGF19 IHC+ patients with radiographic tumor shrinkage, including 1 confirmed PR 7 of 10 FGF19 IHC+ patients remain on treatment MTD and recommended dose for expansion (600 mg QD) provide

  38. Slide 38: Next steps

    Next steps BLU-285 in GIST Continue dose escalation to define an MTD and to maximize clinical activity in KIT-driven patients Increase the cohort sizes in the expansion to evaluate the potential of BLU-285 as a single agent therapy in PDGFR-driven and KIT-driven GIST Seek guidance from the FDA on th

  39. Slide 39: Questions & Answers

    Sbiveprint.. Questions & Answers

Blueprint Medicines — Technical Presentation (December 2016) on 6ix